GGrantIndex
← Search

Shared Resource: Transgenic Mouse Facility

$101,706P30FY2020CANIH

Research Inst Of Fox Chase Can Ctr, Philadelphia PA

Investigators

Linked publications, trials & patents

Paper 39604567Paper 39602533Paper 39554190Paper 39546469Paper 39521739Paper 39514554Paper 39371220Paper 39345610Paper 39343653Paper 39223207Paper 39207123Paper 39189642Paper 39148468Paper 39137728Paper 39072643Paper 39060143Paper 39013784Paper 39003201Paper 38982062Paper 38976159Paper 38963567Paper 38914477Paper 38871720Paper 38865671Paper 38853421Paper 38835516Paper 38815457Paper 38811332Paper 38798370Paper 38766032Paper 38747616Paper 38678525Paper 38659828Paper 38639476Paper 38638131Paper 38600381Paper 38586274Paper 38586042Paper 38559274Paper 38547779Paper 38539515Paper 38464238Paper 38452871Paper 38432028Paper 38421650Paper 38377387Trial NCT04290585Trial NCT03177057Trial NCT02594826Trial NCT02132884Trial NCT02132858Trial NCT02132845Trial NCT02110953Trial NCT02092714Trial NCT02050009Trial NCT01982591Trial NCT01962948Trial NCT01934179Trial NCT01840150Trial NCT01462630Trial NCT01316757Trial NCT01212822Trial NCT00750009Trial NCT00509626Trial NCT00458588Trial NCT00436397Trial NCT00433524Trial NCT00084591Trial NCT00084539Trial NCT00084526Trial NCT00084513Trial NCT00066677Trial NCT00062322Trial NCT00062309Trial NCT00043108Trial NCT00039520Trial NCT00039507Trial NCT00022308Trial NCT00021398Trial NCT00021372Trial NCT00021346Trial NCT00021333Trial NCT00021320Trial NCT00005037Trial NCT00003264Trial NCT00003263Trial NCT00003109Patent 9533040Patent 9182383Patent 9101603Patent 8980258Patent 8685658Patent 8609437Patent 8580263Patent 8329873Patent 7332585Patent 7332580Patent 7129057Patent 6946275Patent 6617427

Abstract

MODEL SYSTEMS SHARED RESOURCE: TRANSGENIC MOUSE FACILITY (TMF) PROJECT SUMMARY/ABSTRACT The Transgenic Mouse Facility (TMF) provides Cancer Center members the ability to introduce manipulated genes and delete or modify endogenous genes in the germline of animals for Cancer Center members. This is a major technological advance in biology, enabling investigators to answer questions about gene function, which often must be analyzed in a whole animal model system. The TMF under the direction of Dietmar Kappes, PhD (BCDF) and 2.0 FTE staff have provided knockout animals that have been instrumental in providing insights into mechanisms of developmental gene regulation, cellular interactions within the immune system, and the effect of oncogenes on growth and differentiation. 22 Cancer Center members used the TMF in calendar year 2014. 95% of TMF users during 2014 were supported by peer-reviewed funding. 29 Cancer Center members from all 5 Research Programs used the TMF in the period 2011-2014. Additionally, TMF services are available to investigators at the Wistar Institute and Thomas Jefferson University (TJU). Since 2012, the TMF has provided service to 6 peer-review funded investigators from Wistar, and 2 peer reviewed funded investigators from TJU. Kappes' years of experience and expertise is key in implementing state-of-the- art technology and innovative approaches. Under Kappes' leadership coupled with institutional investment of $81,498 TMF capabilities were improved by purchasing a new inverted microscope with Differential Interference Contrast (DIC) optics, new micromanipulators for handling and injecting embryos, and a Hamilton Thorne laser drilling system. The TMF has utilized zinc finger nuclease (ZFN)-mediated gene targeting extensively and has recently added and validated the capacity to use CRISPR-mediated gene targeting. These approaches considerably accelerate and simplify the generation of knockout and knock-in mice, and allow generation of complex mouse models with multiple genetic alterations that were not previously feasible. Due to the complexity of the services provided and the cost and caliber of the specialized instrumentation, these services are best facilitated though the centralized TMF. Additional value added is that all Transgenic and Knockout Projects were successful in 2014, resulting in several lines of each desired transgenic or knockout strain. The Facility's 100% success rate attests to its high technical standards and rigorous quality control procedures. Cryopreservation services offered by the TMF provides valuable insurance against loss of irreplaceable mouse lines. The TMF is advised by a dedicated Facility Advisory Committee (FAC) that meets annually. Recommendations from the FAC are directed to a governing Facility Parent Oversight Committee that serves to ensure that the TMF continues to have the necessary resources to provide the highest quality services for Cancer Center members. Demand for services is expected to increase in the next cycle of the CCSG due to plans to recruit in all 5 Programs, and new demand from Cancer Center members at TU. Additionally, TMF services will continue to be available to two nearby institutions, the Wistar Institute and TJU.

View original record on NIH RePORTER →